Display search results for ** instead (2 products)

2 Item(s)

This issue of Vital Signs, released on February 4, 2014, discusses Roches collaboration with Foundation Medicine, Novartis potential anti-aging drug, and DNA Electronics; acquisition of nanoMR, Inc.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

USD 450.00

USD 337.50 save 25 %

2 Item(s)